### **Electronic Supplementary Information**

# MoS<sub>2</sub> nanosheets effectively binds to the receptor binding domain of SARS-CoV-2 spike protein and destabilizes the spike-human ACE2 receptor interactions

Deepali Bisht<sup>1</sup>, Soumya Lipsa Rath<sup>\*2</sup>, Shounak Roy<sup>1</sup> and Amit Jaiswal<sup>\*1</sup>

<sup>1</sup>School of Biosciences and Bioengineering, Indian Institute of Technology, Mandi,

Kamand-175075, Himachal Pradesh, India.<sup>2</sup>

Department of Biotechnology, National Institute of Technology Warangal (NITW),

Warangal -506004, Telangana, India.

\* Corresponding Author Email: j.amit@iitmandi.ac.in; slrath@nitw.ac.in

Table S1 Description of the hotspot region of the Spike and ACE2 receptor protein<sup>1</sup>

Protein	Hotspot region	Function
	210 541	Receptor binding domain
Spike	319-341	(RBD)
glycoprotein		
	437-508	Receptor binding motif (RBM)
	30-42	SARS-CoV-2 spike
ACE2	82-84	glycoprotein interacting amino
	353-357	acid

## Table S2 List of all the systems for MD simulation

S. No.	System	Time (ns)
1	RBD-MoS <sub>2</sub> -1	100
2	RBD-MoS <sub>2</sub> -2	200
3	ACE2-MoS <sub>2</sub> -1	100
4	ACE2-MoS <sub>2</sub> -2	100
5	RBD-ACE2-MoS <sub>2</sub> -1	100
6	RBD-ACE2-MoS <sub>2</sub> -2	100
7	RBD-ACE2-MoS <sub>2</sub> -3	100



**Figure S1.** Docking conformation of smaller, 10×10×6 Å (in white) and larger, 17×16×6 Å (in yellow) MoS<sub>2</sub> nanosheets with A) RBD, B) ACE2 and, C) RBD/ACE2 complex.



**Figure S2** Time evolution of the RMSD of Spike RBD showing protein stability when bound to MoS<sub>2</sub> nanosheet. (Color: RBD- MoS<sub>2</sub>-1 is shown in red and RBD- MoS<sub>2</sub>-2 is shown in black).



**Figure S3** Superimposed structures of the initial and final conformations of A) RBD-MoS<sub>2</sub>-1 B) RBD-MoS<sub>2</sub>-2 C) ACE2-MoS<sub>2</sub>-1 and, D) ACE2-MoS<sub>2</sub>-2, showing the relative position of protein and larger MoS<sub>2</sub> nanosheet ( $17 \times 16 \times 6$  Å).



**Figure S4** The total number of Hydrogen bonds, electrostatic and van der Waal's interaction before (in sea-green) and after simulation (in orange).

System	Nanosheet	Type of	Dock	ing	MD simulation		
		bond	Donor	Acceptor	Donor	Acceptor	
RBD-MoS <sub>2</sub> -1	17×16×6	hydrogen	TYR369:HH	MD07:S7	:MD01:S3	:GLY381:O	
		bond					
			TYR380:HH	MD06:S7	:MD03:S3	:ASP427:O	
			GLY381:HN	MD02:S7	:MD04:S5	:CYS379:O	
			GLY381:HN	MD04:S1	:MD06:S1	:PRO412:O	
			GLY381:HN	MD05:S3	:MD06:S1	:ASP427:O	
			GLN414:HE2	MD06:S5	:MD06:S5	:PRO412:O	
			2				
			MD01:S5	GLY381:O	:MD07:S1	:CYS379:O	
			MD03:S5	ASP427:O	:MD09:S5	:ARG408:O	
			MD06:S1	PRO412:0	:MD09:S5	:GLN414:OE1	
			MD06:S5	PRO412:O	:LYS378:HZ3	:MD08:S7	
					:GLY381:HN	:MD01:S5	
					:GLY381:HN	:MD02:S7	
					:GLY381:HN	:MD04:S1	
		metallic	MD06:MO2	PRO412:O	:MD09:MO2	:GLN414:OE1	
		pi-donor	MD05:S5	TYR380			
		hydrogen					
		bond					
		sulfur-x	MD05:S1	TYR380	:MD03:S7	:ASP427:O	
		pi-sulfur	MD06:S3	TYR380	:MD05:S3	:TYR380	
			MD06:S5	TYR380	:MD05:S5	:TYR380	
					:MD08:S1	:TYR380	
RBD-MoS <sub>2</sub> -2	17×16×6	hydrogen	THR470:HG1	MD01:S5	:MD02:S1	:TYR351:OH	

|--|

	GLU484:HN	MD07:S3	:MD02:S3	:THR470:OG1
	MD04:S3	GLY482:O	:MD03:S3	:TYR351:OH
	MD04:S7	GLY482:O	:MD03:S5	:SER349:OG
	MD06:S5	TYR449:O	:MD04:S1	:THR470:O
	MD07:S1	GLU484:OE	:MD04:S3	:GLY482:O
		2		
	MD07:S7	GLU484:O	:MD04:S7	:GLY482:O
			:MD06:S5	:TYR451:O
			:MD07:S5	:GLU484:OE2
			:MD08:S3	:GLU484:OE2
			:SER349:HG	:MD03:S1
			:GLU484:HN	:MD07:S3
metallic	MD06:MO2	TYR449:O	:MD06:MO2	:TYR449:O
pi-donor			:MD05:S5	:PHE490
hydrogen				
bond				
pi-sulfur	MD02:S7	PHE490	:MD02:S1	:TYR351
	MD03:S3	TYR351	:MD02:S5	:TYR351
	MD04:S1	PHE490	:MD03:S3	:TYR351
	MD05:S1	PHE490	:MD03:S5	:TYR351
	MD05:S7	PHE490	:MD05:S7	:PHE490
	MD09:S5	TYR449	:MD09:S5	:TYR449

\*MD0X: here MD=MoS<sub>2</sub>, 0X=0 chain number

	Niener	Type of	Docki	ng	MD simulation		
System	Inanosneet	bond	Donor	Acceptor	Donor	Acceptor	
ACE2-MoS <sub>2</sub> -1	17×16×6	hydrogen bond	SER47:HG	MD04:S8	: MD01:S2	: ASN63:O	
			SER70:HG	MD02:S8	: MD01:S4	: MET62:O	
			SER106:HN	MD03:S5	: MD01:S4	: ASN63:O	
			ASN117:HD22	MD02:S1	:MD02:S2	:ASP67:OD1	
			ASP350:HN	MD07:S8	:MD03:S1	:SER105:O	
			MD01:S6	ASP67:OD 1	:MD03:S6	:SER106:OG	
			MD07:S7	ALA348:O	:MD04:S4	:SER47:OG	
			MD08:S5	A:ASN394 :OD1	:MD07:S3	:ALA348:O	
			MD09:S8	LEU391:O	:MD07:S4	:ALA348:O	
					:MD07:S7	:ALA348:O	
					:MD07:S8	:ALA348:O	
					:MD09:S6	:LEU391:O	
					:SER43:HG	:MD01:S8	
					:SER43:HG	:MD04:S4	
					:TRP69:HE1	:MD05:S4	
					:TRP69:HE1	:MD05:S8	
					:ASN117:HD21	:MD02:S1	
					:ASN117:HD22	:MD03:S3	
					:ASP350:HN	:MD07:S4	
					:ASN394:HD21	:MD08:S7	
		metallic			:MD03:MO2	:SER106:OG	

Table S3(B) Interactions in Docking and MD simulation for ACE2 and  $MOS_2^*$ 

						<b>TD D</b> (0)
		pi-sulfur	MD05:S4	TRP69	:MD04:S2	:TRP69
			MD05:S6	TRP69	:MD04:S3	:TRP349
			MD07:S6	PHE40	:MD04:S4	:TRP349
			MD08:S2	TRP69	:MD04:S6	:PHE40
			MD08:S2	TRP69	:MD04:S6	:TRP69
			MD08:S4	PHE40	:MD04:S8	:PHE40
					:MD04:S8	:TRP349
					:MD04:S8	:TRP349
					:MD05:S8	:TRP69
					:MD05:S8	:TRP69
					:MD07:S4	:PHE40
					:MD08:S2	:TRP69
					:MD08:S2	:TRP69
					:MD08:S2	:PHE390
					:MD08:S4	:PHE390
					:MD08:S6	:PHE390
		sulfur-x	MD02:S8	SER70:OG		
ACE2-MoS <sub>2</sub> -2	17×16×6	hydrogen	ASN322:HD21	MD06:S5	:MD01:S3	:ALA384:O
			ASN322:HD21	MD09:S1	:MD03:S1	:THR548:O
			GLN325:HN	MD08:S5	:MD03:S5	:GLY319:O
			GLN325:HN	MD08:S7	:MD04:S3	:MET383:O
			MD07:S7	LYS353:O	:MD06:S5	:ASN322:OD1
					:MD07:S7	:GLN325:OE1
					:MD07:S7	:GLY354:O
					:MD07:S8	:GLN325:OE1
					:MD08:S1	:ASN322:O
					:MD08:S5	:MET323:O
					:ASN322:HN	:MD05:S5

			·ASN322·HN	·MD06·S7
			.//01/022.111	
			:GLN325:HN	:MD07:S5
pi-sulfur	MD01:S1	PHE555	:MD01:S3	:PHE555
	MD01-85	PHE555	·MD02·S3	·PHE555
	111201.55	1112333	.101202.05	
• 1				

\*MD0X: here MD=MoS<sub>2</sub>, 0X=0 chain number

## Table S3(C) Interaction in Docking and MD simulation for RBD/ACE2 complex and $MOS_2^*$

D		Type of	Docking		MD simulation		
Protein name	Nanosneet	bond	Donor	Acceptor	Donor	Acceptor	
			CYS344:HN	MD03:S7	A:TRP349:HE1	X:MD03:S5	
			MD03:S5	ALA342:0	A:VAL404:HN	X:MD07:S3	
			MD06:S1	CYS344:SG	A:GLY405:HN	X:MD07:S7	
					A:ARG518:HH12	X:MD04:S8	
		hydrogen			A:GLN522:HE21	X:MD07:S8	
		bond			X:MD03:S1	A:ASN51:OD1	
					X:MD06:S1	A:PRO346:O	
					X:MD06:S5	A:PRO346:O	
RBD-ACE2-	17×1(×(				X:MD07:S4	A:GLU402:O	
MoS <sub>2</sub> -1	1/×10×0				X:MD07:S7	A:GLY405:O	
		metallic			X:MD03:MO1	A:ASN51:OD1	
		pi-donor					
		hydrogen			V.MD02.62	A. TD D2 40	
		bond;pi-			X:MD05:55	A:1KP349	
		sulfur					
		pi-donor					
		hydrogen	MD07:S8	PHE274	MD03:S3	TRP349	
		bond					

	pi-sulfur	MD01:S4	TYR127	MD03:S1	TRP48
	Ĩ	MD01:S4	PHE504	MD09:S7	HIS374
		MD01:S7	PHE504		
		MD01:S8	TYR127		
		MD04:S5	HIS345		
		MD05:S3	HIS345		
		MD05:S7	HIS345		
		MD07:S7	PHE274		
	hydrogen bond	ASN322:HD2 2	MD04:S1	A:ASN322:HN	X:MD02:S7
		MD01:S1	GLN325:OE1	A:ASN322:HN	X:MD02:S5
		MD03:S5	MET383:O	X:MD01:S1	A:MET323:O
		MD09:S1	GLY319:O	X:MD01:S1	A:GLN325:OE1
		MD09:S3	GLY319:O	X:MD02:S3	A:MET323:O
		MD09:S5	GLN552:OE1	X:MD02:S1	A:ASN322:O
				X:MD02:S5	A:ASN322:O
RBD-ACE2-				X:MD04:S1	A:ASN322:OD 1
M10S2-2				X:MD05:S5	A:LEU320:O
				X:MD09:S1	A:GLN552:OE1
	metallic	MD09:MO2	GLN552:OE1		
	pi-donor				
	hydrogen	MD06·S5	PHE555	X·MD06:85	A-PHE555
	bond;pi-	111200.00	11111555	71.1112-00.05	· · · · · · · · · · · · · · · · · · ·
	sulfur				
	(pi-sulfur)	MD03:S1	PHE356		



Figure S5. Interacting amino acid residues of RBD with smaller the  $MoS_2$  nanosheet ( $10 \times 10 \times 6$  Å).  $MoS_2$  is shown in spheres where Mo is shown in teal and S in yellow colors. Amino acid residues are labelled. Dashed Green lines- Hydrogen bonds; Dashed Yellow lines - van der Waal's interactions.



**Figure S6** A) Time evolution of RMSD of human ACE2 receptor bound to larger MoS<sub>2</sub> nanosheet  $(17 \times 16 \times 6 \text{ Å})$  and its corresponding B) Atomic fluctuation of Ca atoms of ACE2 from the crystal structure 6M0J C) Root Mean Square Fluctuations (RMSF) of system ACE2-MoS<sub>2</sub>-1 and ACE2-MoS<sub>2</sub>-2 (color: ACE2-MoS<sub>2</sub>-1 in black ACE2-MoS<sub>2</sub>-2 in red) C) Distribution of secondary structure elements in different ACE2 complexes.



**Figure S7** A) Time evolution of RMSD of RBD/ACE2 complex bound to larger MoS<sub>2</sub> nanosheet (17×16×6 Å) and its corresponding B) Atomic fluctuation of Cα atoms of RBD-ACE2 from the crystal structure 6M0J C) Root Mean Square Fluctuations (RMSF) of system RBD-ACE2-MoS<sub>2</sub>-1 and RBD-ACE2-MoS<sub>2</sub>-2 (color: RBD-ACE2-MoS<sub>2</sub>-1 in black and RBD-ACE2-MoS<sub>2</sub>-2 in red) D) The distribution of secondary structure elements in different RBD-ACE2 systems after simulation.



**Figure S8** A) The time evolution of RMSD of RBD/ACE2 complex bound to larger  $MoS_2$  nanosheet (17×16×6 Å) (color: RBD-ACE2-MoS<sub>2</sub>-1 in black; RBD-ACE2-MoS<sub>2</sub>-2 in red and RBD-ACE2- MoS<sub>2</sub>-3 in green) and the distribution of B) secondary structure elements in the three RBD-ACE2 systems considered for the study.

#### **MATERIALS AND METHODS**

The docking studies were performed using AutoDock which uses semi empirical method which evaluates the binding in two steps. In step one, the energy is estimated from the unbound to bound state and the second step involves the calculation of intermolecular energetics of protein and ligand.

$$\Delta G = (V_{bound}^{L-L} - V_{unbound}^{L-L}) + (V_{bound}^{P-P} - V_{unbound}^{P-P}) + (V_{bound}^{P-L} - V_{unbound}^{P-L} + \Delta S_{conf})$$

$$V = W_{vdw} \sum_{i,j} \left( \frac{A_{ij}}{r_{ij}^{12}} - \frac{B_{ij}}{r_{ij}^{6}} \right) + W_{hbond} \sum_{i,j} E(t) \left( \frac{C_{ij}}{r_{ij}^{12}} - \frac{D_{ij}}{r_{ij}^{10}} \right) + W_{elec} \sum_{i,j} \frac{q_i q_j}{e(r_{ij})r_{ij}} + W_{sol} \sum_{i,j} \left( S_i V_j + S_j V_i \right) e^{(-r_{ij}^2/2\sigma^2)}$$

Here, L refers to the "ligand" and P refers to the "protein" in a ligand-protein docking calculation. Further details can be found in the user manual of Autodock which is freely available<sup>2</sup>.

#### References

1. Unal, M. A.; Bayrakdar, F.; Nazir, H.; Besbinar, O.; Gurcan, C.; Lozano, N.; Arellano, L. M.; Yalcin, S.; Panatli, O.; Celik, D., Graphene Oxide Nanosheets Interact and Interfere with SARS-CoV-2 Surface Proteins and Cell Receptors to Inhibit Infectivity. *Small* **2021**, *17* (25), 2101483.

2. User Guide, AutoDock Version 4.2, https://autodock.scripps.edu/wp-content/uploads/sites/56/2021/10/AutoDock4.2.6\_UserGuide.pdf